A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Primary Sclerosing Cholangitis
In brief
The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
Key facts
- Study ID
- NCT04024813
- Run by
- Gilead Sciences
- People needed
- 1
- Starts
- 2019-11-12
- Expected to finish
- 2020-01-09
- Last updated by the study team
- 2025-01-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sutter Pacific Medical Foundation - California Pacific Medical Center — San Francisco, California, United States
- University of Colorado Denver and Hospital — Aurora, Colorado, United States
- Schiff Center for Liver Diseases/University of Miami — Miami, Florida, United States
- Piedmont Atlanta Hospital — Atlanta, Georgia, United States
- Henry Ford Health System — Novi, Michigan, United States
- New York University — New York, New York, United States
- Liver Institute of Virginia — Newport News, Virginia, United States
- Bon Secours Liver Institute of Richmond — Richmond, Virginia, United States
- Toronto Centre for Liver Disease-Toronto General Hospital — Toronto, Ontario, Canada
- ID Clinic — Mysłowice, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.